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Abstract: Genetic testing in survivors of sudden cardiac arrest (SCA) with a suspicious cardiac phenotype
is considered clinically useful, whereas its value in the absence of phenotype is disputed. We aimed to
evaluate the clinical utility of genetic testing in survivors of SCA with or without cardiac phenotype. Sixty
unrelated SCA survivors (median age: 34 [interquartile range 20 to 43] years, 82% male) without coronary
artery disease were included: 24 (40%) with detectable cardiac phenotype (Ph(+)SCA) after the SCA
event and 36 (60%) with no clear cardiac phenotype (Ph(-)SCA). The targeted exome sequencing was
performed using the TruSight-One Sequencing Panel (Illumina). Variants in 185 clinically relevant cardiac
genes with minor allele frequency <1% were analyzed. A total of 32 pathogenic or likely pathogenic
variants were found in 27 (45%) patients: 17 (71%) in the Ph(+)SCA group and 10 (28%) in the Ph(-)SCA
group. Sixteen (67%) Ph(+)SCA patients hosted mutations congruent with the suspected phenotype,
in which 12 (50%) were cardiomyopathies and 4 (17%) channelopathies. In Ph(-)SCA cases, 6 (17%)
carried a mutation in cardiac ion channel genes that could explain the event. The additional 4 (11%)
mutations in this group, could not explain the phenotype and require additional studies. In conclusion,
cardiac genetic testing was positive in nearly 2/3 patients of the Ph(+)SCA group and in 1/6 of the
Ph(-)SCA group. The test was useful in both groups to identify or confirm an inherited heart disease,
with an important impact on the patient care and first-degree relatives at risk.
DOI: https://doi.org/10.1016/j.amjcard.2019.02.061
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Genetic testing in survivors of sudden cardiac arrest (SCA) with a suspicious cardiac phenotype 
is considered clinically useful, whereas its value in the absence of phenotype is disputed. We 
aimed to evaluate the clinical utility of genetic testing in survivors of SCA with or without 
cardiac phenotype. Sixty unrelated SCA survivors (median age: 34 [IQR 20-43] years, 82% 
male) without coronary artery disease were included: 24 (40%) with detectable cardiac phenotype 
(Ph(+)SCA) after the SCA event and 36 (60%) with no clear cardiac phenotype (Ph(−)SCA). 
Either targeted exome sequencing was performed using the TruSight-One Sequencing Panel 
(Illumina). Variants in 185 clinically relevant cardiac genes with minor allele frequency <1% 
were analyzed. A total of 32 pathogenic or likely pathogenic variants were found in 27 (45%) 
patients: 17 (71%) in the Ph(+)SCA group and 10 (28%) in the Ph(−)SCA group. Sixteen (67%) 
Ph(+)SCA patients hosted mutations congruent with the suspected phenotype, in which 12 (50%) 
were cardiomyopathies and 4 (17%) channelopathies. Among Ph(−)SCA cases, 6 (17%) carried a 
mutation in cardiac ion channel genes that could explain the event. The additional 4 (11%) 
mutations in this group, could not explain the phenotype and require additional studies. In 
conclusion, cardiac genetic testing was positive in nearly 2/3 patients of the Ph(+)SCA group and 
in 1/6 of the Ph(–)SCA group. The test was useful in both groups to identify or confirm an 
inherited heart disease, with an important impact on the patient care and first-degree relatives at 
risk. 
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          Sudden cardiac arrest (SCA) is a common manifestation of a wide spectrum of inherited 
and acquired cardiovascular diseases, and extra-cardiac pathologies.
1
 Identifying the cause of 
SCA is essential for proper management of the arrhythmic substrate to allow a personalized 
approach. The detection of a specific cardiomyopathy or inherited arrhythmia phenotype in a 
SCA survivor (Ph(+)SCA) allows genetic testing for confirmation of the clinical diagnosis, risk 
stratification, and eventually specific therapy.
2, 3
 Phenotype-guided genetic testing has shown a 
heterogeneous diagnostic yield of 9-60% in SCA survivors, depending on the panel and 
technology used.
4-6
 In the absence of a clear cardiac phenotype, the event is referred to as a 
phenotype-negative SCA (Ph(–)SCA), or idiopathic ventricular fibrillation.7 Genetic testing in 
Ph(–)SCA has been discouraged by the expert consensus (class III) to avoid possible over-
diagnosis and unnecessary interventions in families owing to potential misinterpretation of 
innocent bystander variants;.
2, 7
 Thus, currently the knowledge on genetic basis of Ph(−)SCA is 
limited. In this study, we sought to evaluate the clinical and genetic characteristics of an 
unselected cohort of SCA survivors referred for genetic testing from different regions of 
Switzerland.  
METHODS 
 In this partly prospective and partly retrospective study we included SCA patients referred 
to the Bern University Hospital for genetic testing between January 2014 and May 2018. SCA 
was defined as an unexpected circulatory arrest with cardiovascular collapse and documented 
hemodynamically unstable sustained ventricular tachycardia (VT) or ventricular fibrillation (VF), 
restored by cardioversion or defibrillation, as appropriate. Internationally accepted criteria were 
used to diagnose/exclude specific diseases. Initial diagnostic workup included personal and 



















computed tomography, exercise stress test (whenever possible); additional examination with 
cardiac MRI, electrophysiological study, or provocative testing were performed when considered 
clinically indicated. Patients with coronary artery disease, myocarditis, sarcoidosis, systemic 
diseases affecting the heart, secondary cardiomyopathies, or reversible causes of SCA were 
excluded from the study. Survivors of SCA with any suspicious or robust cardiac phenotype 
(Ph(+)SCA) and those with no identified phenotype (Ph(–)SCA) were included in this study. This 
study was conducted in full agreement with the principles outlined in the Declaration of Helsinki. 
The study protocol was approved by the Ethical Commission of the Canton Bern.  
 Genomic DNA was extracted from EDTA-blood using standard procedures. Clinical 
exome analysis was performed using next-generation sequencing on MiSeq or NextSeq 500 
instrument using either the TruSight One or TruSight One expanded Sequencing Panel (Illumina, 
San Diego, CA), which provide comprehensive coverage of exons and flanking intronic 
sequences of 4813 and 6794 clinically relevant genes, respectively. The intronic coverage 
comprised at least 30 to 50bp of each intron; the coverage depth of exons was minimum 30x. 
After sequencing, variants in 185 genes associated with hereditary cardiovascular diseases were 
analyzed (Supplementary Table 1). Read alignment and local realignment of indels were 
performed using CLC Genomic Workbench v7.5.1 or CLC Biomedical Genomic Workbench 
v5.0 (Qiagen, Redwood City, CA). Novel or putative disease-associated variants were analyzed 
using the following filtering criteria: protein’s primary structure, species conservation of the 
affected amino acid and an allele frequency <1% based on the 1000 Genome Project database. 
Exonic variants below 1% frequency in the Exome Aggregation Consortium browser, including 
+/- 8bp flanking intronic variants, were further analyzed. For titin (TTN), only radical mutations 
(i.e. nonsense, frameshift, and splice-site mutations) were considered as putative pathogenic 



















established by the American College of Medical Genetics and Genomics (ACMG).
8
  
 Categorical variables are presented as numbers and percentages; quantitative variables are 
presented as median (interquartile range [IQR]) for non-normally distributed variables. 
Categorical variables were compared using Chi-Square or Fisher’s exact test, as appropriate. 
Continuous variables were compared using Student’s t test or Mann–Whitney U test, as 
appropriate. To adjust for multiple testing, we used Bonferroni adjustment and set alpha at 0.005. 
Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 25.0. IBM 
Corp. All tests were 2-tailed, with a p<0.05 considered significant. 
RESULTS 
 Sixty unrelated SCA patients (median age 34 [20-43] years; male–82%) without 
previously known heart disease, including 24 (40%) with (Ph(+)SCA) and 36 (60%) with 
Ph(−)SCA, were enrolled (Table 1). The two groups were similar in terms of age at SCA and 
gender distribution. Data regarding the circumstances of SCA were available in 28 (47%) 
patients. In 13 (22%) cases the event occurred at the time or shortly after exercise activities and 
in 15 (25%) occurred unrelated to sports activities. The proportion of exercise-related SCA cases 
were similar in both groups (19% vs 25%, p=0.609). Twelve (92%) out of 13 exercise-related 
SCA cases occurred in males, but males were not more likely to experience a SCA during 
exercise, than the females (p=0.263).   
 Overall, 32 putative pathogenic variants (14 novel and 18 previously reported) were 
identified in 27 (45%) out of 60 subjects (Table 2). No variants have been identified more than 
once in our cohort. Patients with exercise-related SCA had a likelihood of having a positive result 
of genetic testing (54%) similar to those with exercise-unrelated (40%) or unknown 
circumstances of SCA (44%; p=0.747).  



















followed by hypertrophic cardiomyopathy (n=4) and arrhythmogenic right-ventricular 
cardiomyopathy (ARVC, n=4). Other phenotypes included left-ventricular non-compaction, 
catecholaminergic polymorphic ventricular tachycardia (CPVT, n=2), mitral valve prolapse 
(n=2), long QT syndrome (n=1), short QT syndrome (n=1), and progressive cardiac conduction 
disease (n=1). Twenty-one putative pathogenic variants were identified in 17 (71%) out of 24 
Ph(+)SCA patients, including 14 (67%) mutations in cardiomyopathy-associated genes (LMNA, 
TNNT2, TNNI3, TTN, FLNC, PKP2, DSP, JPH2, TNXB, LAMP2, BAG3, and CAV3) and 7 (33%) 
in cardiac ion channel genes (RYR2, CASQ2, SCN5A, KCNQ1, and HCN4). In 13 out of 17 (76%) 
genotype-positive patients a cardiomyopathy and in 4 (24%) cardiac channelopathy was 
suspected (Figure 1). Sixteen (67%) out of 24 Ph(+)SCA patients carried mutations in agreement 
with the observed phenotype, whereas 1 patient, a 31-year-old male, carried a likely pathogenic 
variant in the CAV3 (caveolin 3) gene, which so far has not been associated with the identified 
DCM phenotype; thus it was considered suspicious but not diagnostic.  
 Overall, 11 pathogenic or likely pathogenic variants were detected in 10 (28%) out of 36 
Ph(−)SCA survivors (Figure 1), which was significantly lower than the 71% diagnostic yield in 
Ph(+)SCA patients (p=0.017). Six (17%) subjects carried mutations in ion channel genes 
(SCN5A, RYR2, and KCNE2), that could explain the SCA in the absence of phenotype (concealed 
channelopathies). Additionally, 5 putative pathogenic variants localized in the RANGRF, ABCC9, 
TRPM4, DSP and TTN did not clarify the SCA event and require further functional studies or 
segregation analysis.  
DISCUSSION 
 In a cohort of 60 SCA survivors without previously known heart disease, the cardiac 
panel genetic testing detected 32 putative pathogenic variants in 27 (45%) cases. In patients with 



















(67%) cases, while in those with no phenotype, the genetic test could clarify the cause of the 
SCA in 6 (17%) cases. Approximately 20% of all patients with SCA were found to have an 
association with sports activities or physical work. 
 Our Ph(+)SCA cohort included cases with a wide variety of cardiac phenotypes, which 
once again highlights the broad spectrum of heritable heart diseases underlying SCA. As 
expected, the diagnostic yield was 2-fold higher in the Ph(+)SCA group than in the Ph(−)SCA. 
Interestingly, the diagnostic yield of 71% in the Ph(+)SCA group surpassed the reported general 
yield for each of the diseases suspected in these patients probably because stronger phenotypes 
are usually associated with higher diagnostic yield of the genetic test. All but one of the 
genotype-positive cases of the Ph(+)SCA group, carried pathogenic variants consistent with the 
suspected heart disease, underscoring that phenotyping remains central to the diagnosis of the 
cause of SCA. Clarifying the clinical role of the potentially disease-causing variants in genes 
unrelated to the phenotypes, such as the CAV3-variant in a patient with DCM, requires further 
research and highlights the utility of broader genetic panels for research purposes.   
The possible genetic nature of SCA in the absence of measurable heart disease has been first 
recognized in 2000, when the p.Ser1710Leu mutant sodium channel has been shown to be the 
likely molecular substrate for Ph(−)SCA.9 Subsequently, detailed experimental and familial 
studies have established the causality for the Dutch founder haplotype in DPP6,
10







 Moreover, recent studies on Ph(–)SCA cohorts found mutations 
in cardiac ion channel genes (RYR2, KCNH2, KCNQ1, KCNE1, SCN5A, and CACNA1C) and 
cardiomyopathy-associated genes (LMNA, TTN, DSP, PLN, DSC2, MYBPC3, MYH7, TNNT2), 
with a diagnostic yield of up to 15%, thus further expanding the spectrum of genes potentially 
associated with Ph(–)SCA.3, 14 We identified a genetic substrate that explains nearly one-sixth of 



















channel genes. This yield is consistent with previous reports,
3, 14, 15
 and highlights that concealed 
cardiac channelopathies may manifest with malignant arrhythmias even in the absence of a 
detectable cardiac phenotype.  
Four out of 6 mutations detected in our Ph(−)SCA cohort were located in RYR2, making CPVT 
the most prevalent diagnosis in this group (11%). Two CPVT patients (#3 and #9) had a history 
of syncopal episodes preceding SCA with no direct link to exercise. Another patient (#5) had 
frequent premature ventricular contractions and a non-sustained VT at maximum exercise load, 
which did not raise a suspicion of CPVT. The fourth patient (#6) had a negative exercise test but 
experienced a VT at follow up terminated with an ICD shock. These data, in line with recent 
reports,
15
 indicate the need for a low threshold to suspect CPVT and to perform a confirmatory 
genetic test in Ph(−)SCA survivors with equivocal stress test findings. 
 The remaining putative pathogenic variants affected genes encoding the ion channel 
TRPM4 (TRPM4), ion channel interacting proteins (RANGRF, ABCC9) or myocardial structural 
proteins (DSP, TTN). Mutations in the TRPM4 channel gene have been implicated in progressive 
familial heart block, atrioventricular block, right bundle-branch block, and Brugada syndrome 
(BrS).
16
 Although the TRPM4 channel is known to be involved in cellular calcium regulation, its 
exact role in the cardiac physiology and pathophysiology remains unclear. Loss-of-function 
RANGRF mutations have been reported to cause BrS through impairing the trafficking of Nav1.5 
channel.
17
 Likewise, gain-of-function mutations in ABCC9, a critical gene for the activation and 
regulation of the KATP channels, were shown to result in increased IKATP current and manifest 
with BrS.
18





Desmoplakin disease has been shown to cause connexin mislocalization and result in significant 
alterations in conduction-repolarization abnormalities prior to morphological changes.
21
 Radical 
mutations in TTN have been linked mainly to DCM,
23



















and are known to confer high arrhythmic potential. Despite the presumed pathogenic role of these 
variants, their potential causality in Ph(−)SCA is subject to further evaluation in functional and 
follow-up studies. These patients would therefore need close surveillance for detection of any 
related phenotype at follow-up. 
 Our findings are particularly interesting in the context of the current HRS/ EHRA 
guidelines, which discourage the use of genetic testing in Ph(−)SCA.2, 7 On the contrary, 
consideration of genetic testing in SADS is recommended (IIa).
2, 7
 The main difference between 
these two groups is that survivors reach the hospital alive and SADS victims to the morgue. 
Previous studies have found a genetic cause in 25% of SADS cases.
24, 25
 In such cases, cascade 
screening reveals a cardiac disease in nearly half of relatives,
6
 who can benefit from regular 
surveillance, lifestyle recommendations, and preventive therapy. Our results indicate that the 
yield of the genetic test in survivors of Ph(−)SCA (17%) is similar to those in SADS victims. 
Additionally, our analysis uncovered cardiomyopathy gene mutations in Ph(–)SCA patients, 
which is in accordance with studies on SADS and requires further studies.
25
 Predictive genetic 




Similar to previous studies, the use of large gene panels in our study led to high yield of VUS, 
particularly in the Ph(–)SCA group (47%). The clinical implication of these variants remain 
elusive and require further studies. Mutations in minor cardiomyopathy or channelopathy genes, 
defined as implicated in <5% of disease cases, were identified in 8 (13%) SCA patients. These 
included mutations in RANGRF, ABCC9, FKTN, KCNE2 in patients with Ph(–)SCA and LAMP2, 
BAG3, HCN4, CAV3, FLNC, and JPH2 in patients with Ph(+)SCA.  
 Our results suggest that genetic testing is useful in all SCA survivors with and without 



















accredited laboratories to avoid potential erroneous assignment of pathogenicity.
3
 Longitudinal 
prognostic studies of a large cohort of genetically tested SCA survivors and their family members 
are necessary to determine the potential role of mutation status for risk stratification. The 
progress in the understanding of the genotype-phenotype associations and the evolving variant 
classification schemes will optimistically solve the puzzle of uncertain variants and provide more 
reliable criteria for assessment of pathogenicity  
 Our study has several limitations. The number of enrolled patients in the present study 
was relatively small, an inherent problem in studies conducted on rare diseases. Our cohort 
included only SCA survivors referred for genetic testing. Although the classification of the 
variants stringently followed the ACMG guidelines, we cannot definitely conclude on their 
pathogenicity in the absence of segregation or functional studies, although this may be hampered 
by an incomplete penetrance of the variants. We did not investigate whether a carrier status of a 
putative pathogenic variant confers a risk for recurrent cardiac events, or whether mutation-
carrier Ph(−)SCA patients develop a phenotype at follow-up. Finally, we lack clinical and genetic 
data of the families, which could help better interpret the impact of many variants.  
 In conclusion, comprehensive cardiac panel genetic testing identified mutations linked to 
channelopathies and/ or cardiomyopathies in nearly half of SCA survivors without previous 
diagnosis of cardiac disease. Genetic testing revealed a putative pathogenic variant compatible 
with the phenotype in 67% of Ph(+)SCA cases. In the Ph(–)SCA group, genetic test revealed the 
cause of arrest in 17% of cases, similar to the yield reported in SADS. Majority of mutations 
identified in Ph(–)SCA patients were associated with channelopathies, most commonly CPVT, 
whereas in the Ph(+)SCA group, the mutations were mostly located in cardiomyopathy-
associated genes. Since genetic testing facilitated the understanding of one-sixth of Ph(–)SCA 



















allows to guide treatment decisions. This study also highlights the need for long-term follow-up 
studies to examine the prognostic value of genetic findings in SCA survivors.  
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Figure 1. The results and the interpretation of genetic test findings in survivors of sudden cardiac 
arrest with and without evident clinical cardiac phenotype. G, genotype; Ph, phenotype; SCA, 
sudden cardiac arrest; VUS, variant of uncertain significance. 
 
Table 1. Demographic characteristics and genetic test results in sudden cardiac arrest survivors 
referred for cardiovascular genetic testing, grouped based on the displayed cardiac phenotype. 
Characteristic All patients 






No. of probands 60 (100%) 24 (40%) 36 (60%) 0.155 
Age at SCA, y, median (IQR) 34 (20-43) 36 (20-46) 34 (20-42) 0.490 
Male gender 49 (82%) 21 (87%) 28 (78%) 0.274 
Patients aged ≤35 yrs 32 (53%) 12 (50%) 20 (56%) 0.673 
Male 27 (84%) 10 (83%) 17 (85%) 0.674 
Female 5 (16%) 2 (17%) 3 (15%)  
Genetic test results     




















Abbreviations: Ph, phenotype; SCA, sudden cardiac arrest; SD, standard deviation; VUS, variant 
of uncertain significance. 
* P values are for binomial test, t-test, Fisher’s exact test, or Chi-Square test, as appropriate. Chi-
Square test was used to test for gender differences between phenotype groups in the whole 
population, as well as in subgroups according to age and genetic test results.  
 
Male 23 (85%) 15 (88%) 8 (80%) 0.561 
Female 4 (15%) 2 (12%) 2 (20%)  
VUS 23 (38%) 5 (21%) 18 (50%)  
Male 18 (78%) 4 (80%) 14 (78%) 0.709 
Female 5 (22%) 1 (20%) 4 (22%)  
Negative 10 (17%) 2 (8%) 8 (22%)  
Male 8 (80%) 2 (100%) 6 (75%) 0.622 



















Table 2. Summary of clinical and genetic characteristics of sudden cardiac arrest survivors. 
Case 
# 





Cardiac Phenotype Circumstances 
of the event 
Gene Reference  
sequence no. 














1 M 56 Ph(−)SCA - exercise unrelated RANGRF NM_16492.4 c.198C>A p.Tyr66* nonsense heterozygous rs1223777741 0.00001758 N/A LP 
      DES NM_001927.3 c.742C>T p.Arg248Cys missense  heterozygous rs772117708 0.000008920 0.000008 VUS 
2 M 17 Ph(−)SCA - unknown SCN5A NM_001099404.1 c.2441G>A  p.Arg814Gln missense  heterozygous rs199473584  0.00003158 0.000018 LP 
      SNTA1 NM_003098.2 c.566C>T  p.Ser189Leu missense  heterozygous rs144860423 0.0003642 0.0002 VUS 
3 F 5 Ph(−)SCA - exercise unrelated RYR2 NM_001035.2 c.6737C>T p.Ser2246Leu missense  heterozygous rs121918597 N/A N/A P 
4 M 17 Ph(−)SCA - exercise-related ABCC9 NM_020297.3 c.1320+1G>A p.(?) splice region heterozygous rs139620148 0.00003899 0.000058 LP 
5 F 17 Ph(−)SCA - exercise unrelated RYR2 NM_001035.2 c.365G>A p.Arg122His missense  homozygous rs727503396 N/A N/A LP 
6 M 47 Ph(−)SCA - unknown RYR2 NM_001035.2 c.1250G>A p.Arg417Gln missense heterozygous rs751428303 0.00001559 0.000025 LP 
7 M 28 Ph(−)SCA - exercise unrelated DSP NM_004415.2 c.4775A>G p.Lys1592Arg missense heterozygous rs200421954 0.0003817 0.000185 LP 
      TTN NM_001256850 c.29732-2A>T p.? splice region heterozygous novel variant N/A N/A P 
8 F 34 Ph(−)SCA - unknown  TRPM4 NM_017636 c.2387T>C p.Leu796Pro missense heterozygous rs1191927360 N/A N/A VUS 
      FKTN NM_001079802 c.1380dupA p.Tyr461Ilefs*? frameshift heterozygous rs775366895 0.00004399 N/A LP* 
9 M 38 Ph(−)SCA - exercise-related RYR2 NM_001035.2 c.1346T>G  p.Ile449Arg missense heterozygous rs373331669 0.00001777 0.000008 LP 
      DSP NM_004415.2 c.2462A>G p.Lys821Arg missense heterozygous novel variant N/A N/A VUS 
10** M 2 Ph(−)SCA - unknown KCNE2 NM_172201.1 c.170T>C  p.Ile57Thr missense heterozygous rs74315448 0.001045 0.0009 P† 
      CACNB2 NM_201593.3 c.410G>A p.Gly137Asp missense heterozygous rs754596850 0.000008799 0.000008 VUS 
11 M 28 Ph(−)SCA - unknown SCN5A NM_001099404.1 c.3929C>T p.Pro1310Leu missense  heterozygous novel variant N/A N/A VUS 
      RYR2 NM_001035.2 c.7570G>A p.Val2524Ile missense  heterozygous rs934248102 0.00003893 N/A VUS 
      TTN NM_001267550.1 c.1545_1549delAGAAA  p.Lys515AsnfsTer2 frameshift heterozygous novel variant N/A N/A LP 
12** M 22 Ph(−)SCA - exercise unrelated KCNQ1 NM_000218.2 c.190_210delCCTGCGTCCCCGGCCGCGCCC p.Pro64_Pro70del deletion heterozygous reported, no 
dbSNP ID 
N/A N/A VUS‡ 
      PKP2 NM_004572.3 c.2431C>A p.Arg811Ser missense  heterozygous rs139734328 0.0009214 0.00087 VUS 
13 M 19 Ph(−)SCA - exercise unrelated AKAP9 NM_005751 c.10664A>T p.Asp3555Val missense  heterozygous rs139046510 0.001444 0.0009 VUS 
      TNXB NM_019105.6 c.5956A>G  p.Ile1986Val  missense  heterozygous rs201365475  0.000008873 N/A VUS 
14 F 41 Ph(−)SCA - exercise-related TNNI3 NM_000363 c.349A>G p.Lys117Glu missense  heterozygous novel variant N/A N/A VUS 
15 M 28 Ph(−)SCA - unknown DSP NM_004415.2 c.2723G>A p.Arg908His missense  heterozygous rs142494121 0.0009762 0.0011 VUS 
      MYH6 NM_002471.3 c.1138G>A p.Glu380Lys missense  heterozygous rs768924353 N/A 0.000008 VUS 
16 M 24 Ph(−)SCA - unknown CTNNA3 NM_001127384 c.2573T>C p.Leu858Ser missense  heterozygous rs41313840 0.0003953 0.0003 VUS 
      KCNE1 NM_001270402.1 c.253G>A p.Asp85Asn missense  heterozygous rs1805128 0.01223 0.0092 VUS 
17 M 35 Ph(−)SCA - exercise-related KCNH2 NM_000238 c.1653C>G p.Phe551Leu missense heterozygous novel variant N/A N/A VUS 
18 M 56 Ph(−)SCA - exercise-related FLNC NM_001458.4 c.1616C>T p.Pro539Leu missense heterozygous rs375570393 0.000 0.000017 VUS 
19 M 41 Ph(−)SCA - unknown ANK2 NM_001148.4 c.4799T>C p.Ile1600Thr missense  heterozygous rs764150279 0.00002342 0.000033 VUS 
      SCN2B NM_004588.4 c.356C>T p.Pro119Leu missense  heterozygous rs767589740 N/A 0.000200 VUS 
20 M 38 Ph(−)SCA - unknown KCNJ2 NM_000891.2 c.973C>T  p.Arg325Cys missense  heterozygous rs202067116 0.00006197 0.000041 VUS 
21 M 31 Ph(−)SCA - unknown KCNJ5 NM_000890 c.155G>A P.Arg52His missense  heterozygous rs144062083  0.00004396 0.000025 VUS 
      FBN1 NM_000138 c.1307A>G p.Tyr436Cys missense  heterozygous novel variant N/A N/A VUS 
22 M 34 Ph(−)SCA - exercise unrelated SCN10A NM_006514.3 c.3675T>G  p.Ile1225Met missense heterozygous rs371834340 0.00008519 0.000017 VUS 



















      KCNE1 NM_000219.4 c.314C>T  p.Ser105Leu missense heterozygous rs780041404 0.00002639 0.000091 VUS 
23 M 46 Ph(−)SCA - exercise-related RYR2 NM_001035.2 c.11018G>A  p.Arg3673Gln missense heterozygous rs778111237  0.00003552 0.000025 VUS 
      SCN1B NM_199037 c.716C>A p.Thr239Asn missense heterozygous novel variant N/A N/A VUS 
      IDH2 NM_002168.3 c.293T>C  p.Ile98Thr missense heterozygous rs139512088 0.00007035 0.000033 VUS  
24 F 57 Ph(−)SCA - exercise unrelated MYH7 NM_000257.3 c.3078G>T p.Lys1026Asn missense heterozygous novel variant N/A N/A VUS 
25 M 48 Ph(−)SCA - unknown MYH6 NM_002471.3 c.4429C>T p.Arg1477Cys missense heterozygous rs201989347 0.00006166 0.000017 VUS 
26 M 33 Ph(−)SCA - unknown KCNH2 NM_000238.3 c.3304A>C p.Thr1102Pro missense heterozygous novel variant N/A N/A VUS 
      KCNH2 NM_000238.3 c.3265A>C p.Thr1089Pro missense heterozygous novel variant N/A N/A VUS 
27 M 24 Ph(−)SCA - exercise unrelated TMEM43 NM_024334.2 c.323T>C p.Val108Ala missense heterozygous rs182351748 0.000 0.0002 VUS 
      MYH6 NM_002471.3 c.982G>A p.Glu328Lys missense heterozygous rs144422878 0.00007752 0.000058 VUS 
28 F 39 Ph(−)SCA - unknown SCN10A NM_006514 c.1355C>T p.Ser452Phe missense heterozygous novel variant N/A N/A VUS 
      SNTA1 NM_003098 c.692C>T p.Pro231Leu missense heterozygous rs559396761 0.000 0.000008 VUS 
      TNXB NM_019105 c.12373G>A p.Glu4125Lys missense heterozygous novel variant N/A N/A VUS 
29 M 60 Ph(−)SCA - unknown N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
30 M 13 Ph(−)SCA - unknown N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
31 F 39 Ph(−)SCA - unknown N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
32 M 19 Ph(−)SCA - exercise-related N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
33 M 18 Ph(−)SCA - unknown N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
34 M 36 Ph(−)SCA - exercise unrelated N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
35 M 42 Ph(−)SCA - unknown N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
36** F 43 Ph(−)SCA - unknown N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
37 F 37 Ph(+)SCA borderline ARVC unknown RYR2 NM_001035.2 c.12665_12667delAGA p.Lys4223del deletion heterozygous novel variant N/A 0.000091 LP 
38 F 24 Ph(+)SCA LVNC/ DCM exercise unrelated LAMP2 NM_002294.2 c.928+1G>T p.(?) splice region heterozygous novel variant N/A N/A P 
39 M 62 Ph(+)SCA LQTS exercise unrelated KCNQ1 NM_000218.2 c.691C>T p.Arg231Cys missense  heterozygous rs199473457 0.00006497 N/A LP 
40 M 15 Ph(+)SCA suspected CPVT unknown RYR2 NM_001035.2 c.8741C>T p.Thr2914Met missense heterozygous rs766484260 0.00001773 0.000035 VUS 
        c.12257G>A p.Arg4086His missense heterozygous rs752977469 0.000008947 0.000009 LP 
41 M 19 Ph(+)SCA DCM/ Laminopathy unknown BAG3 NM_004281 c.803C>A p.Ser268* nonsense heterozygous novel variant N/A N/A P 
42 M 69 Ph(+)SCA possible HCM unknown TNNT2 NM_001001430.2 c.860G>A p.Trp287* nonsense heterozygous rs727504247 0.000 0.000011 P 
43 M 41 Ph(+)SCA PCCD unknown SCN5A NM_198056.2 c.3840+1G>A p.(?) splice region heterozygous rs1366120635 0.000008801 N/A P 
      CTNNA3 NM_013266.2 c.2097C>G p.Asn699Lys missense heterozygous rs142942346 N/A N/A VUS 
      ANK2 NM_001148.5 c.10825C>A p.Leu3609Ile missense heterozygous novel variant N/A N/A VUS 
44 M 45 Ph(+)SCA LVNC unknown HCN4 NM_005477.2 c.1435A>G p.Ile479Val missense heterozygous novel variant N/A N/A P 
        c.1454C>A p.Ala485Glu missense heterozygous novel variant N/A N/A P 
45 M 22 Ph(+)SCA CPVT unknown CASQ2  NM_001232.3 c.872_880delTTGCCCGGG p.Val291_Arg294del deletion homozygous novel variant N/A N/A P 
46 M 23 Ph(+)SCA HCM exercise-related TNNT2 NM_001001430.2 c.275G>T p.Arg92Gln missense heterozygous novel variant N/A N/A P 
47 M 35 Ph(+)SCA ARVC unknown PKP2 NM_001005242 c.148_151delACAG p.Thr50Serfs*61 frameshift heterozygous rs397516997 N/A N/A P 
48 M 14 Ph(+)SCA DCM unknown LMNA NM_170707.3 c.1621C>T p.Arg541Cys missense heterozygous rs56984562 N/A N/A P 
49 M 14 Ph(+)SCA HCM exercise-related TNNI3 NM_000363 c.485G>C p.Arg162Pro missense heterozygous rs397516354 0.00005302 N/A P 
50 M 31 Ph(+)SCA DCM exercise-related CAV3 NM_001234.4 c.*6+2T>G p.(?) splice region heterozygous novel variant N/A N/A LP 
      MYH6 NM_002471.3 c.4193G>A p.Arg1398Gln missense heterozygous rs150815925 0.0005653 0.0004 VUS 
51 M 63 Ph(+)SCA DCM exercise-related DSP NM_004415.2 c.5326G>T p.Glu1776* stop-gain heterozygous novel variant N/A N/A P 
      EYA4 NM_172103 c.1340G>T p.Gly447Val missense heterozygous novel variant N/A N/A VUS 
52 M 31 Ph(+)SCA DCM exercise-related DSP NM_001008844  c.3562T>C p.Tyr1188His missense heterozygous rs141508330 0.0001401 0.000067 LP 
      FLNC NM_001127487 c.5199+1G>T p.? splice region heterozygous rs1465588989 0.00006484 N/A P 



















      TNXB NM_019105.6 c.10990G>A p.Val3664Met missense heterozygous novel variant N/A N/A LP 
53 M 43 Ph(+)SCA DCM unknown TTN NM_001256850 c.44440dupA p.Thr14814Ansfs*7 frameshift heterozygous novel variant N/A N/A LP 
54 M 9 Ph(+)SCA possible ARVC unknown DSG2 NM_001943.2 c.877A>G p.Ile293Val missense  heterozygous rs2230234  0.08733 0.0687 VUS 
      DSP NM_004415.2 c.6208G>A p.Asp2070Asn missense  heterozygous rs41302885 0.005636 0.0039 VUS 
55 M 42 Ph(+)SCA MVP exercise unrelated TNXB NM_019105.6 c.8734G>A p.Gly2912Ser missense heterozygous novel variant N/A 0.0007 VUS 
      MYLK NM_053025.3 c.4169A>C p.Asn1390Thr missense heterozygous novel variant N/A N/A VUS 
      HCN4 NM_005477.2 c.2800C>T p.Arg934Cys missense heterozygous rs199638465  0.00008081 0.0006 VUS 
56 M 40 Ph(+)SCA HCM unknown TMPO NM_003276 c.689G>A p.Arg230His missense heterozygous rs758666714 0.00002324 0.000025 VUS 
      AKAP9 NM_005751 c.9830T>C  p.lle3277Thr missense heterozygous rs144021475 0.0001937 0.000008 VUS 
      GJD4 NM_153368  c.259C>T p.Leu87Phe missense heterozygous rs76906304 0.01812 0.013 VUS 
57 F 17 Ph(+)SCA suspected SQTS unknown CACNA2D1 NM_000722 c.2264G>C p.Ser755Thr missense heterozygous rs151327713 0.0006633 0.0008 VUS 
58 M 47 Ph(+)SCA MVP exercise unrelated MYH6 NM_002471 c.2383C>T p.Arg795Trp missense heterozygous rs202120238 0.0002014 0.000074 VUS 
59 M 50 Ph(+)SCA possible ARVC exercise-related N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
60 M 59 Ph(+)SCA DCM exercise unrelated N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
 
Abbreviations: ACMG, American College of Medical Genetics and Genomics; ARVC, arrhythmogenic right ventricular 
cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LP, likely pathogenic; LVNC, left ventricular 
non-compaction; MVP, mitral valve prolapse; P, pathogenic; Ph, phenotype; SCA, sudden cardiac arrest; SD, standard deviation; 
SQTS, short QT syndrome; VUS, variant of uncertain significance. N/A denotes ‘not applicable’. 
* FKTN-mediated diseases (DCM or muscular dystrophy-dystroglycanopathy) are transmitted as an autosomal-recessive trait; 
therefore, the identified heterozygous pathogenic variant is not considered to have a direct link to the SCA.   
** Indicates patients who were successfully resuscitated, but died during hospitalization due to neurological complications caused by 
prolonged cerebral ischemia  
† This variant has been initially interpreted as pathogenic; however, the recent evidence suggests contradictory results, and the variant 
may also be considered as VUS.  
‡ This variant has been initially interpreted as pathogenic based on the available literature, but has been later reclassified as a VUS 
after additional in vitro patch clump experiments and segregation studies revealed no evidence of pathogenicity.
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